Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer

   
Brovkina O.I.1 , Gordiev M.G.2, Toropovskiy A.N.3, Khodyrev D.S.1, Enikeev R.F.2, Gusev O.A.4, Shigapova L.H.5, Nikitin A.G.1

1. Federal Research and Clinical Center, FMBA of Russia, Moscow, Russia
2. Tatarstan Cancer Center, Kazan, Russia
3. LLC “TestGene”, Ulianovsk, Russia
4. Kazan Federal University, Kazan, Russia; RIKEN, Yokohama, Japan
5. Kazan Federal University, Kazan, Russia
Section: Experimental Study
DOI: 10.18097/PBMC20166206638      PubMed Id: 28026806
Year: 2016  Volume: 62  Issue: 6  Pages: 638-644
The presence of activating mutations in the EGFR gene influences cell proliferation, angiogenesis, and increases metastatic ability; it has a significant impact on the choice of medical therapy of non-small cell lung cancer (NSCLC). The use of targeted therapy with tyrosine kinase inhibitors requires performance of appropriate genetic tests. The aim of this study was to design a real-time PCR-based diagnostic kit for fast and cheap of EGFR mutations testing in paraffin blocks and plasma, and kit validation using samples from patients with NSCLC, and also comparative estimation of diagnostic features of real-time PCR with wild type blocking and digital PCR for mutation testing in blood plasma. The study included 156 patients with various types of adenocarcinoma differentiation. It was designed a simple and efficient real-time PCR-based method of detecting L858R activating mutation and del19 deletion in the EGFR gene for DNA isolated from paraffin blocks. Kit for EGFR mutations was validated using 411 samples of paraffin blocks. The proposed system showed high efficiency for DNA testing from paraffin blocks: a concordance with results of testing with therascreen® EGFR RGQ PCR Kit (`Qiagen`, Germany) was 100%. It has been shown the possibility of using this test system for the detection of mutations in plasma
Download PDF:  
Keywords: activating mutations in EGFR gene, real-time PCR, non-small cell lung cancer, plasma
Citation:

Brovkina, O. I., Gordiev, M. G., Toropovskiy, A. N., Khodyrev, D. S., Enikeev, R. F., Gusev, O. A., Shigapova, L. H., Nikitin, A. G. (2016). Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer. Biomeditsinskaya Khimiya, 62(6), 638-644.
This paper is also available as the English translation: 10.1134/S1990750817030027
References  
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)